SLNO
- Soleno Therapeutics, Inc.
()
Overview
Company Summary
Soleno Therapeutics, Inc. (SLNO) is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for rare diseases. Specifically, Soleno Therapeutics specializes in the treatment of conditions that affect the central nervous system.
The company aims to provide innovative solutions for patients with limited treatment options by developing novel therapies. They focus on rare diseases that have no approved treatments or their existing treatments are inadequate.
Soleno Therapeutics primarily focuses on two key therapeutic areas: Prader-Willi Syndrome (PWS) and through its subsidiary, Capnia, Inc., Pulmonary Arterial Hypertension (PAH). Prader-Willi Syndrome is a complex genetic disorder that affects various systems in the body, particularly the endocrine system and the central nervous system. Soleno Therapeutics is developing a product called Diazoxide Choline Controlled-Release (DCCR) capsules as a potential treatment for the hyperphagia and obesity associated with PWS.
In addition to PWS, Soleno Therapeutics works on developing therapies for Pulmonary Arterial Hypertension (PAH), a condition characterized by high blood pressure in the arteries of the lungs. PAH is a severe and debilitating disease with limited treatment options. Soleno's subsidiary, Capnia, is developing a device called the CoSense End-Tidal Carbon Monoxide (ETCO) Monitor for the early detection of abnormally high blood levels of carbon monoxide, which can be a sign of PAH.
The ultimate goal of Soleno Therapeutics is to develop innovative therapies that can significantly improve the lives of patients suffering from rare diseases with unmet medical needs. By focusing on these specific areas, Soleno aims to make a positive impact on the lives of patients, their families, and the healthcare community.